Management

Image of Ali Fattaey, Ph.D.

Dr. Fattaey has served as the company’s Director, President and Chief Executive Officer since June 2014. He joined the company in 2013 as President and Chief Operating Officer.
 

Previous experience:
President, Chief Executive Officer and Director, ACT Biotech, Inc.
Vice President, Research, Chiron Corporation (acquired by Novartis)
Chief Scientific Officer, Sagres Discovery (acquired by Chiron)
Vice President, Research, Onyx Pharmaceuticals – palbociclib (acquired by Amgen)
Director, EpiTherapeutics ApS (acquired by Gilead)
Director, Melanoma Therapeutics Foundation, a non-profit organization
Research Fellow, Medicine, Harvard Medical School, Massachusetts General Hospital
Ph.D. in Microbiology, Kansas State University
 

Image of James Dentzer

Mr. Dentzer joined the company in March 2016. 
 

Previous experience:
Chief Financial Officer, Dicerna Pharmaceuticals
Chief Financial Officer, Valeritas
Chief Financial Officer, Amicus Therapeutics
VP & Corporate Controller, Biogen
Various Positions at DuPont, Kemper Financial Services and Bank of America Merrill Lynch (formerly Bank of Boston)
MBA, University of Chicago, and BA, Boston College
 

Image of David Tuck, M.D.

Dr. Tuck has served as Curis’ Senior Vice President of Clinical and Translational Sciences since January 2016.  He joined the company in 2015 as Vice President of Clinical and Translational Sciences.
 

Previous experience:
Senior Medical Director, Oncology Translational Innovation, EMD Serono
Translational Physician, Ipilimumab and External Development of immune checkpoint inhibitors, Bristol-Myers Squibb
Associate Professor, Head of a Cancer Genomics and Bioinformatics Lab, Yale University
Associate Director, Yale Comprehensive Cancer Center
Director, Oncology Clinical Research (Taxol and novel anti-cancer compounds), Bristol-Myers Squibb
MD, University of Vermont and Board Certified in Internal medicine, Medical oncology and Hematology
 

Image of Mani Mohindru, Ph.D.

Dr. Mohindru has served as Curis’ Senior Vice President of Corporate Strategy since April 2015.  She joined the company in 2013 as Vice President of Corporate Strategy and Investor Relations.
 

Previous experience:
Co-founder, Immtox, LLC., a privately-held biotechnology company
Biotechnology equity research analyst, ThinkEquity, Credit Suisse and UBS
Managing Director, Investment Banking, Capstone Investments
Pharma and Biotech Industry Consultant, Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health)
Ph.D. in Neurosciences, Northwestern University, and Masters in Biotechnology, AIIMS, India
 

Image of Tania Chander, PharmD

Dr. Chander has served as Vice President of Product Developmet and Program Management since July 2016.  She joined the company in July 2013 as Vice President of Product Development.
 

Previous experience:
Associate Director, Oncology Product Development Team Leader, MedImmune, LLC (AstraZeneca)
Manager, Virology Medical Strategy, Bristol-Myers Squibb
Post-Doctoral Oncology Pharmacy Fellowship, Bristol-Myers Squibb
PharmD in Pharmacy, Rutgers University
 

Image of Minji Kim, Ph.D., MBA

Dr. Kim has served as Vice President of Corporate and Business Development since May 2015.  She joined the company in 2013 as Director of Corporate and Business Development.
 

Previous experience:
Technology Scout/Associate, Global Business Development & Licensing - Oncology, Hoffmann-La Roche, Inc. 
Instructor, Harvard Medical School and Mass General Hospital, Alzheimer’s disease research
Ph.D. in Molecular and Cell Biology, Seoul National University, South Korea, and M.B.A, Yale University
 

Image of Mark Noel

Mr. Noel joined Curis in March 2001.
 

Previous experience:
Vice President, Customer Relations and Senior Director, Program Management, Gene Logic, Inc.
Acting Deputy Director, Office of Technology Development, National Cancer Institute
Patent Agent, Patent, Trademark and Regulatory Affairs Department of Gist Brocades NV (The Netherlands)
BS, University of Maryland
 

Image of Frank Waligora, MBA

Mr. Waligora has served as Curis’ Vice President, CMC, since 2015.  He joined the company in 2011 as Director, CMC


Previous experience:
Director, CMC, Idera Pharmaceuticals
Director, CMC, Ziopharm Oncology
Chemical Process Development, Idenix and Triangle Pharmaceuticals
MBA, Northeastern University, and BS in Chemistry, Rochester Institute of Technology
 

Image of Tim Wyant Ph.D.

Dr. Wyant joined Curis in December, 2015 as Senior Director of Cancer Immunology.
 

Previous experience:
Director, Translational Medicine, Pharmacodynamic and Biomarker Group (AdcetrisTM, EntyvioTM), Takeda (formally Millennium Pharmaceuticals)
Scientist, Immunology, Biomarker Discovery, SurroMed
Faculty (part-time), Northeastern University, New Vaccine Technologies
Chair, Biomarkers in Translational Medicine Focus Group, American Association of Pharmaceutical Scientist (AAPS)
Co-chair, AAPS ligand binding focus group’s action program committee on biomarker assays
Post-Doctoral Fellow, University of Maryland Center for Vaccine Development
Ph.D. in Immunology, University of Arizona
 

Image of Lisa Massmanian

Lisa joined Curis in April, 2015 as Director of Clinical Operations.
 

Previous experience:
Clinical Team Lead, TESARO, Inc.
Senior Clinical Trial Manager, Clinical Operations, Merrimack Pharmaceuticals
Clinical Research Scientist, Clinical Pharmacology, AVEO Pharmaceuticals, Inc.
Research Associate III, Clinical Pharmacology, ImmunoGen, Inc.
ABI Coordinator, Arqule Biomedical Institute
Product Discovery Scientific Administration, University of Massachusetts Medical School
Master of Science in Regulatory Affairs for Drugs, Biologics, and Medical Devices from Northeastern University
 

Image of Robert Booher, Ph.D.

Dr. Booher joined Curis in September, 2015 as Associate Director of Translation Sciences.
 

Previous experience:
Associate Principal Scientist, Merck Research Laboratory
Associate Director, Biology-Research, Chiron Corporation (acquired by Novartis)
Associate Director, Discovery Research, Sagres Discovery (acquired by Chiron)
Senior Scientist, Rigel Pharmaceuticals
Senior Scientist, Research, Onyx Pharmaceuticals (acquired by Amgen)
Research Fellow, Cell biology, Harvard Medical School
Research Fellow, Biochemistry and Biophysics, University of California, San Francisco
Ph.D. in Genetics, Stony Brook University